X0306 4 2023-03-03 0 0001679082 Myovant Sciences Ltd. MYOV 0001798550 Sumitomo Chemical Co., Ltd. 7-1 NIHONBASHI 2-CHOME CHUO-KU, TOKYO M0 103-6020 JAPAN 0 0 1 0 0001446601 Sumitomo Pharma Co., Ltd. 6-8 DOSHOMACHI 2-CHOME CHUO-KU, OSAKA M0 541-0045 JAPAN 0 0 1 0 0001798244 Sumitovant Biopharma Ltd. 7TH FLOOR 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM 0 0 1 0 Common Shares 2023-03-03 4 J 0 4243005 0.00 D 45798176 I See Footnote Option (Right to Acquire) 27.00 2023-03-03 4 J 0 1 0.00 A 2023-03-03 2023-03-30 Common Shares 4243005 1 I See Footnote On March 3, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") voluntarily returned to Roivant Sciences Ltd., a Bermuda exempted company limited by shares ("Roivant"), for no consideration, 4,243,005 common shares, par value $0.000017727 per share (each, a "Common Share") of Myovant Sciences Ltd. (the "Issuer") subject to that certain Share Return Agreement, dated as of December 27, 2019, by and among Sumitovant, Roivant and Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma") (the "Share Return"). In addition, Sumitovant, Sumitomo Pharma and Roivant agreed that, in the event that the Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the "Merger Agreement"), by and among the Issuer, Sumitovant, Zeus Sciences Ltd. and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma, is terminated in accordance with its terms, Roivant will return such Common Shares to Sumitovant. Sumitovant directly owns 45,798,176 Common Shares following the Share Return. Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma, which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the "Option") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023. Sumitomo Chemical Co., Ltd., By: /s/ Takeo Kitayama, Executive Officer, General Manager, Corporate Planning Office 2023-03-06 Sumitomo Pharma Co., Ltd., By: /s/ Tsutomu Nakagawa, Senior Director, Global Corporate Strategy 2023-03-06 Sumitovant Biopharma Ltd., By: /s/ Monika Adams, Transactions Officer 2023-03-06